#USA #Trailhead Biosystems #Beachwood #Endothelial Cells #iPSC cells

Trailhead Biosystems Expands its Innovative Product Line

Trailhead Biosystems, Inc., a pioneering biotechnology enterprise, has recently launched its TrailBio® Endothelial Cells, marking a significant advancement in the realm of human cellular research. This new product offers a validated model of the human vascular endothelium derived from induced pluripotent stem cells (iPSCs).

The Innovation Behind TrailBio® Endothelial Cells

TrailBio® Endothelial Cells are meticulously developed through the company's proprietary platform, the High‑Dimensional Design-of-Experiments (HD-DoE®). This cutting-edge approach ensures that researchers receive not only a high-quality product but one that is both consistent and scalable, drastically reducing experimental variability typically associated with primary donor-derived cells.

Key Features and Functional Validation

The product stands out due to its rigorous validation, demonstrating key endothelial markers such as CD31, CD144, and von Willebrand Factor. With a purity level exceeding 90%, these endothelial cells have been put to the test across various in vitro assays, showcasing their ability to undergo angiogenic tube formation and react to inflammatory stimuli.

A crucial advantage of TrailBio® Endothelial Cells is their readiness for immediate use upon thawing, provided in cryopreserved vials containing 1 million viable cells. Importantly, these cells can also be cultured and expanded for at least three passages without losing their phenotype or functionality, making them a versatile tool for researchers.

Addressing Research Needs

According to David Llewellyn, CEO of Trailhead Biosystems, the debut of TrailBio® Endothelial Cells is a major step forward in their iPSC-derived cell portfolio. "These cells merge functional performance with the reproducibility offered by our HD-DoE® platform, providing a reliable model that circumvents various issues faced with primary cell systems," he noted.

The applications of TrailBio® Endothelial Cells are extensive, encompassing angiogenesis research, inflammation studies, and drug screening as well as toxicity testing. This versatility allows researchers to utilize these cells in both discovery and translational research, paving the way for potential therapeutic advancements that could significantly impact clinical practices.

Promising Responses and Future Potential

Angelica Gomes Ueltschy, Scientific Director at Trailhead, emphasized the balanced attributes of these endothelial cells, remarking that their proven angiogenic and inflammatory responses make them ideal for studying vascular biology. "These represent a pivotal asset in evaluating therapeutic candidates within controlled and repeatable assays," she expressed.

For those interested in exploring this innovative product, more details and cell characterization data are accessible through the company’s website at www.trailbio.com.

About Trailhead Biosystems

Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead Biosystems is committed to developing human cells characterized by defined molecular and functional properties specifically designed for drug discovery and regenerative medicine. Their integration of mathematic modeling and high-throughput robotics within the HD-DoE® platform positions them at the forefront of cellular research.

For press inquiries, contact Tim Mauk at Trailhead Biosystems, who is available to discuss this launch further.